Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series

Anastasia Martynova1 · Victor Chiu1 · Melissa Mert1 · David Hermel1 · Ilene Ceil Weitz1

Received: 28 March 2020 / Accepted: 3 January 2021
© The Author(s) 2021

Abstract
First-line treatment of aplastic anemia (AA) and for AA patients ineligible for hematopoietic stem cell transplantation (HSCT) has consisted of antithymocyte globulin (ATG), the calcineurin inhibitor cyclosporine A (CsA), and more recently eltrombopag. However, at our institution, we have successfully substituted another calcineurin inhibitor, tacrolimus, as a part of immunosuppressive therapy (IST) for AA due to more favorable toxicity profile. Since there is limited data on the use of tacrolimus in aplastic anemia, we conducted a retrospective review of twenty patients treated with tacrolimus-based immunosuppressive therapy (IST) as a first- or second-line treatment. The overall response rate was comparable to that of patients treated with CsA (18 patients). However, there were no cutaneous side effects observed in patients receiving tacrolimus, a relatively common finding with CsA use. Our data suggest that tacrolimus-based IST is a potential option in AA and might have a more favorable toxicity profile compared to CsA.

Keywords Aplastic anemia · Immunosuppressive therapy · Tacrolimus · Eltrombopag · Cyclosporine

Introduction
Immunosuppressive therapy (IST) is the cornerstone of acquired aplastic anemia treatment in adults who are of advanced age or do not have an allogeneic bone marrow transplant (BMT) donor available. Treatment with immunosuppressive therapy (IST) using the combination of antithymocyte globulin (ATG) and cyclosporine A (CsA), with the more recent addition of thrombopoietin receptor (TPO) agonist, eltrombopag, has been shown to be an effective and safe first-line regimen [1, 2]. Published response rates range from 50 to 70%, with the majority of patients achieving long-term survival [3, 4]. While many second-line therapies have been recommended, outside of hematopoietic stem cell transplantation (HSCT), there is limited data on the efficacy and safety of therapies for adult patients who have failed to respond to CsA or developed CsA-associated toxicities [4, 5].

Cyclosporine and tacrolimus are widely used in post-allogenic bone marrow as well as in solid organ transplant patients to prevent graft vs host or acute rejection [6–11]. The mechanism of action of both drugs is the suppression of T cell activation via downregulation of calcineurin, leading to decreased intranuclear translocation of nuclear factor of activated T cells (NFAT). Tacrolimus is a macrolide antibiotic that binds FK-binding protein, while cyclosporine is a lipophilic cyclic eleven amino acid peptide that binds to cyclophilins [12]. As an immunosuppressive agent, tacrolimus is approximately 100 times more potent than cyclosporine [13]. There are case series of successful use of tacrolimus as part of an immunosuppressive therapy regimen in pediatric patients with aplastic anemia [14, 15]. However, IST using tacrolimus has not been well described in adult patients with AA. To our knowledge, only one study has been published describing the use of tacrolimus for aplastic anemia in adults [16]. Zhu et al. used rabbit anti-thymocyte globulin (ATG) instead of horse ATG, which is more often used in the first-line setting in the USA [2, 17]. There is no data using tacrolimus and eltrombopag.

Differences in toxicity profiles between the two agents have been described in the solid organ transplantation literature and suggest that tacrolimus may be an attractive treatment
alternative to cyclosporine. Toxicities associated with cyclosporine such as acute kidney injury, hypertension, neuropsychiatric symptoms, and cutaneous side effects such as gum hypertrophy and hirsutism are common, especially in women [18, 19]. Tacrolimus causes less cutaneous toxicities in renal transplant patients, and is associated with less calcineurin inhibitor-associated nephrotoxicity [20, 21]. Patients receiving tacrolimus after lung transplant have lower incidence of bronchiolitis obliterans and hypertension [9]. A systemic review also showed less hypertension, hyperlipidemia, and cutaneous toxicities in patients who received tacrolimus after heart transplant compared to those that received cyclosporine [7].

In this study, we retrospectively examined the safety profile and effectiveness of tacrolimus combined with ATG with and without eltrombopag, in both first-line and second-line immunosuppressive therapy in patients at an urban academic medical center.

**Methods**

This study was a retrospective case series conducted at the University of Southern California Norris Comprehensive Cancer Center and LAC+USC Medical Center. Using ICD-9 codes, we searched the administrative databases of these two large hospital systems serving a diverse, urban population. Patients with new or established diagnosis of aplastic anemia (AA) who received either cyclosporine (CsA), tacrolimus, or both as part of an immunosuppressive regimen from 2008 to 2017 were included in this series. We abstracted baseline demographic and laboratory data for these patients, as well as details regarding immunosuppression, hematologic response, and toxicities from treatment. We used the Camitta criteria to classify severity of aplastic anemia as moderate, severe, and very severe [22]. Response was evaluated at 3, 6, 9, and 12 months after therapy initiation. Complete response (CR) was defined as hemoglobin (Hgb) > 10 g/dL, absolute neutrophil count (ANC) > 1000, and a platelet count > 100,000 cells/mcL maintained for at least 3 months. Partial response (PR) for patients starting with very severe or severe aplastic anemia was defined as achieving hematologic indices that did not meet criteria for CR, but no longer met Camitta criteria for severe aplastic anemia. PR for patients starting with moderate aplastic anemia was defined as transfusion independence and an improvement in at least one cell line as follows: Hgb increase by 3 g/dL, ANC by 500 cells/mcL, and platelet count improvement by 20,000 cells/mcL. Relapse was defined as declining blood counts no longer meeting criteria for PR. The overall response rate corresponded to the proportion of patients who had a partial or complete response. Acute kidney injury (AKI) was defined as increase in creatinine > 1.5 mg/dL times baseline.

**Compliance with ethical standards**

This study was approved by the University of Southern California Institutional Review Board (USC IRB) in accordance with the World Medical Association’s Declaration of Helsinki. Because this was a retrospective chart review and patients were de-identified, informed consent was not required by the USC IRB. No relevant conflict of interest was identified for the authors ICW, AM, VC, MM, and DH.

This paper was funded by a gift from the Tilley Family Foundation.

**Statistical analysis**

Categorical variables are reported as absolute number and percentage; continuous variables are reported as median (interquartile range [IQR]). Differences in demographics and baseline characteristics by first line of treatment were tested by Fisher’s exact test or exact Wilcoxon rank sum test, as appropriate. Differences in treatment response at 3, 6, and 12 months were tested by Fisher’s exact test. Statistical significance was set at $p < 0.05$. All statistical analyses were performed using SAS 9.4.

**Results**

We identified 36 patients with aplastic anemia who were treated with either CsA, tacrolimus, or both. Six patients were excluded from the final analysis due to lost of follow-up within 2 months of presentation. Of the remaining 30 patients, 20 patients received CsA + ATG and 10 patients received tacrolimus + ATG IST as first-line treatment. All but one patient received horse ATG as a part of IST and the remaining one patient in CsA group received rabbit ATG. Three patients proceeded with HSCT within 1 year of IST initiation. Out of those 3, one patient had moderate AA, one severe AA, and one very severe AA. Patients with severe and very severe AA received CsA + ATG as initial IST after diagnosis. One patient had only partial response and proceeded his treatment with haploidentical BMT. The other patient was nonresponder and had salvage therapy with allogenic stem cell transplant. The remaining patient with moderate AA initially that received tacrolimus + eltrombopag was nonresponder and proceed with HSCT.

There were 18 females and 12 males with a median (IQR) age of 46 (32–67) years. Fifty percent of the study patients were Latino. Tacrolimus was initialed at 3 mg twice daily. Of all patients who received tacrolimus as either line therapy (21), twelve received eltrombopag as a part of IST. Eltrombopag was initiated at 150 mg daily in Caucasian and African American patients, 75 mg daily in Asian patients. In all but one patient, eltrombopag was started within 3 weeks of IST.
initiation (median time 6 days). The remaining one patient was started 2 months after IST initiation due to insurance issues.

Patients taking tacrolimus vs. cyclosporine as initial therapy did not differ in terms of demographics, although patients receiving first-line tacrolimus were significantly more likely to be concurrently taking eltrombopag compared to patients taking cyclosporine (81.8% vs. 36.8% respectively; \( p = 0.01 \); Table 1). This is due to majority of patients in tacrolimus cohort being diagnosed and treated after eltrombopag was reported to improve hematopoiesis in severe AA [23].

The response and duration of tacrolimus therapy were described in Table 2. Toxicities of any kind were not statistically significantly different by first-line therapy (Table 3). All seven patients that stopped cyclosporine therapy due to toxicity (three with gingival hyperplasia, three with hirsutism, one with transaminitis) were switched to tacrolimus maintenance therapy and experienced resolution of the above side effects within 3 months after CsA discontinuation.

In six patients treated with tacrolimus, medication was held secondary to toxicity (4 AKI, 2 transaminitis, Table 3). Five of six patients were able to restart tacrolimus at the lower dose upon resolution of the adverse event and one patient was started on CsA as an alternative therapy. None of the toxicities recurred with subsequent treatment. The odds of experiencing acute kidney injury for patients on tacrolimus compared to CsA was not statistically significant (\( p = 0.54 \)).

Patients who received tacrolimus as a second-line IST \( (n = 11) \) did not experience any mucocutaneous side effects, hirsutism, or gum hyperplasia that they had experience with their first-line cyclosporine treatment (Table 3). The median (IQR) change in the number of toxicities was 0 (−1–0), which was not statistically significantly difference from 0 based on the Wilcoxon signed rank test (\( p = 0.13 \)). In the patients receiving tacrolimus, there were no additional toxicities associated with the addition of eltrombopag.

**Discussion**

HSCT remains a first-line treatment option for patients diagnosed with severe AA but may not be feasible for some patients available. Our study primarily consists of patients from financially disadvantaged population who were not able to proceed with HSCT due to lack of insurance or absence of matched sibling donor. Our case series supports the use of tacrolimus as a viable treatment option for adult patients with AA. As we reported previously, tacrolimus showed durable response in majority of patients in both first-line and second-line treatment groups [24]. Although CsA had previously been the standard

| Characteristic               | Total (n=30) | Cyclosporine (n=20) | Tacrolimus (n=10) | \( p \) value |
|-----------------------------|-------------|---------------------|-------------------|--------------|
| Age, years                  | 46 (32–67)  | 43 (35–66)          | 48 (32–69)        | 0.86         |
| Gender                      |             |                     |                   |              |
| Female                      | 18 (60.0%)  | 11 (52.6%)          | 7 (72.7%)         | 0.41         |
| Male                        | 12 (40.0%)  | 9 (47.3%)           | 3 (27.2%)         |              |
| Ethnicity                   |             |                     |                   |              |
| Asian                       | 5 (16.6%)   | 4 (21.0%)           | 1 (9.0%)          | 0.66         |
| Hispanic                    | 15 (50%)    | 10 (47.3%)          | 5 (54.5%)         |              |
| White                       | 10 (33.3%)  | 6 (31.5%)           | 4 (36.3%)         |              |
| Severity *                  |             |                     |                   |              |
| Moderate                    | 10 (33.3%)  | 7 (36.8%)           | 3 (27.2%)         | 0.25         |
| Severe                      | 9 (30%)     | 4 (15.7%)           | 5 (54.5%)         |              |
| Very severe                 | 6 (20%)     | 4 (21.0%)           | 2 (18.1%)         |              |
| BM cellularity, %           | 10 (5–10)   | 10 (5–10)           | 10 (5–10)         | 0.66         |
| Horse antitimocyte globulin | 27 (90%)    | 17 (84.2%)          | 9 (90.9%)         | >0.99        |
| Rabbit antitimocyte globulin| 3 (10%)     | 3 (15.7%)           | 0                 | 0.53         |
| Emtrombopag use             | 17 (56.6%)  | 8 (36.8%)           | 8 (81.8%)         | 0.01         |
| Length of follow-up (days)  | 955.0 (768.0–1739.0) | 1159.5 (832.0–2264.0) | 708 (438–780) | – |

Results are reported as median (IQR) or \( N \) (%), as appropriate

*5 missing observations in cyclosporine group
| Pt# | Age (years), gender | Ethnicity | Severity of AA | Clinical PNH | Eltrombopag use | Type of ATG | Time to TI (days) | Response at 3 months | Response at 6 months | Response at 12 months | Duration of tacrolimus treatment (days) | Time to relapse (days) | Length of follow-up (days) | Tacrolimus side effects |
|-----|---------------------|-----------|----------------|--------------|-----------------|-------------|-------------------|----------------------|----------------------|---------------------|-------------------------------|-----------------------|------------------------|------------------------|
| 1*  | 27, F               | Asian     | Very severe    | No           | Yes             | Horse       | 29                | PR                   | CR                   | CR                  | 404                           |                       | 404                    |                        |
| 2*  | 69, F               | White     | Moderate       | No           | Yes             | Horse       | N/A               | PR                   | PR                   | PR                  | 1031                          |                       | 1031                   | AKI                    |
| 3*  | 48, M               | Hispanic  | Moderate       | No           | Yes             | Horse       | 79                | NR                   | PR                   | PR                  | 438                           |                       | 438                    |                        |
| 4*  | 43, F               | Hispanic  | Severe         | No           | No              | Horse       | 191               | PR                   | PR                   | PR                  | 337                           | 487                   | 768                    | AKI                    |
| 5*  | 32, M               | Hispanic  | Severe         | No           | No              | Horse       | 37                | PR                   | PR                   | PR                  | 817                           | 416                   | 1014                   |                        |
| 6*  | 23, M               | Hispanic  | Severe         | No           | Yes             | Horse       | 114               | PR                   | PR                   | PR                  | 784                           | 486                   |                        |                        |
| 7*  | 71, F               | White     | Severe         | No           | No              | Horse       | N/A               | PR                   | PR                   | PR                  | N/A                           | 106                   |                        | 106                    |
| 8*  | 73, F               | White     | Severe         | No           | Yes             | Horse       | 18                | CR                   | CR                   | PR                  | 780                           | 416                   | 780                    |                        |
| 9*  | 52, F               | White     | Very severe    | No           | Yes             | Horse       | 113               | NR                   | PR                   | PR                  | 708                           | 364                   | 708                    | AKI                    |
| 10* | 45, M               | Hispanic  | Moderate       | Yes          | No              | Horse       | 0                 | CR                   | CR                   | CR                  | N/A                           |                       |                        |                        |
| 11  | 26, F               | Asian     | Very severe    | No           | No              | Horse       | N/A               | PR                   | CR                   | CR                  | 1151                          |                       | 1335                   |                        |
| 12  | 35, F               | Hispanic  | Moderate       | No           | Yes             | Horse       | 7                 | NR                   | PR                   | PR                  | 968                           |                       | 968                    | AKI                    |
| 13  | 25, M               | Hispanic  | Severe         | No           | No              | Horse       | 13                | PR                   | PR                   | CR                  | 1760                          |                       | 1971                   | Gynecomastia            |
| 14  | 26, M               | White     | Severe         | No           | No              | Horse       | 0                 | CR                   | CR                   | CR                  | 465                           |                       | 912                    |                        |
| 15  | 66, M               | White     | Moderate       | No           | Yes             | Horse       | N/A               | NR                   | NR                   | NR                  | 809                           |                       | 809                    |                        |
| 16  | 38, F               | White     | Moderate       | Yes          | No              | Horse       | N/A               | NR                   | NR                   | NR                  | 775                           |                       | 775                    |                        |
| 17  | 70, F               | Hispanic  | Moderate       | Yes          | No              | Horse       | 84                | NR                   | NR                   | NR                  | 832                           |                       | 832                    |                        |
| 18  | 35, F               | White     | Very severe    | No           | Yes             | Horse       | N/A               | PR                   | PR                   | PR                  | 250                           | 984                   | 955                    | Transaminitis           |
| 19  | 35, F               | Hispanic  | Very severe    | No           | Yes             | Horse       | N/A               | NR                   | NR                   | NR                  | 795                           |                       |                        |                        |
| 20  | 29, F               | Asian     | Moderate       | Yes          | No              | Rabbit      | N/A               | NR                   | NR                   | NR                  | 578                           |                       | 826                    | AKI                    |
| 21  | 47, M               | Hispanic  | Severe         | No           | No              | Horse       | N/A               | NR                   | PR                   | PR                  | 757                           |                       | 757                    | Transaminitis           |

*First-line tacrolimus-based immunosuppressive therapy
+ Patient received HSCT during the treatment course

Top 10 patients received tacrolimus + ATG as a first-line IST at the time of diagnosis. The remainder 11 patients were switched to tacrolimus maintenance therapy due to poor response to Cyclosporin A (13, 15, 18, 20) or intolerable toxicities (11, 12, 14, 16, 17, 19, 21). Of patients switched due to toxicities, patient #10 was in PR on CsA at the time of switching, and all other patients did not achieve desirable response on CsA; however, the primary reason to switch medication was development of toxicity which in most cases was AKI. At the time of the last review, 4 patients (8, 12, 14, 21) were weaned off tacrolimus and continued to remain in remission, 12 patients remained on tacrolimus therapy, 3 stopped tacrolimus due to adverse events, and 1 patient was lost of follow-up. Of 21, 3 patients (5, 8, 9) experienced relapse while on tacrolimus therapy and received second induction therapy with ATG + tacrolimus with response. One patient in this cohort (10) proceeded with HSCT (Pt patient; AA aplastic anemia; PNH paroxysmal nocturnal hemoglobinuria; ATG anti-thymocyte globulin; TI transfusion independence; AKI acute kidney injury; HSCT hematopoietic stem cell transplantation; PR partial response; CR complete response; NR no response; N/A not applicable)
treatment option, in our institution, tacrolimus + ATG has been employed as a first-line IST as it showed better tolerability in the individual cases. The choice of tacrolimus therapy was mostly physician and patient driven due to unwanted cutaneous side effects to CsA leading to poor compliance.

Tacrolimus was well tolerated, and all patients remained on medication beyond 12 months. Two patients were lost of follow-up. Although the number of patients treated with tacrolimus was limited, our results did not show a difference in response with use of tacrolimus compared with CsA. The overall response rate was similar to that seen with ATG + CSA, but relapse was observed more frequently in the CsA group compared to tacrolimus group, 39% vs 15%, during a long period of follow-up.

Our findings are comparable to other studies examining first-line tacrolimus-based IST. In a study in pediatric population by Alsultan et al, an 88% complete response rate to tacrolimus + ATG as first-line IST was observed compared to 85% for CsA + ATG [14]. Similarly, the study by Zhu et al. reported an 85% OR rate and 54% CR rate in the tacrolimus group. In our series, 33% of patients achieved CR with tacrolimus and 55% with CsA at 12 months [16].

Observed toxicities in both groups were similar. Nephrotoxicity was the most common and clinically significant adverse effect of both groups although all the patients experienced resolution of AKI following medication cessation. AKI recurrence seemed to be similar in rate as well, suggesting that switching from CsA to tacrolimus due to AKI may not be not warranted. However, as expected, there was a clear increase in hirsutism and gingival hyperplasia with CsA. As aplastic anemia tends to effect younger age patients, these cosmetic side effects may lead to reduced therapy compliance and limit its overall use. Notably, in the CsA cohort, hirsutism was the reason of CsA discontinuation in 3 patients, two of whom were young females and one male.

Our study also describes the use and safety of concurrent administration of the TPO-agonist eltrombopag and tacrolimus. Eltrombopag plus standard IST using horse ATG and CsA has been demonstrated to improve blood counts and efficacy of the IST in the setting of refractory aplastic anemia. However it’s use in combination with tacrolimus has never been described [1, 25, 26]. In our study, most of the patients treated with any line tacrolimus received concurrent eltrombopag. It was well tolerated without an increase in toxicity. Treatment with eltrombopag has been reported to be associated with liver toxicity, which is a side effect of tacrolimus as well. In our cohort, only two patients treated with tacrolimus developed grade 3 elevation of liver enzymes. Only one received the tacrolimus and eltrombopag combination. Other patients who received both medications concurrently did not experience any hepatic toxicity, including transaminitis of any grade or other side effects. The combination appears to be effective and safe.

This is a relatively large case series of ethnically diverse patients with a rare hematologic disease for which there is limited data on treatment options. Our data set is unique in that half of our patients were from Latin America, where the incidence of AA is relatively low [27]. The majority of the patients in our cohort were patients in a resource-poor setting where bone marrow transplantation was not an option due to financial constraints. While these data show a favorable response rate to first-line tacrolimus, perhaps the most striking observation is that a large proportion of patients who do not tolerate CsA or who had not achieved a CR on CsA did achieve improved responses on tacrolimus. Notably, the median relapse-free survival for CsA users should be interpreted with caution as 27% of patients who failed first-line CsA and then proceeded with second-line tacrolimus have not been evaluated for response to CsA due to lack of data.

### Table 3

| Toxicity                        | Cyclosporine (n=20) | Tacrolimus (n=10) | Cyclosporine | Tacrolimus |
|---------------------------------|---------------------|-------------------|-------------|------------|
| Acute kidney injury             | 7 (38.9%)           | 3 (33.3%)         | 2 (18.2%)   | 2 (18.2%)  |
| Skin                            | 1 (5.6%)            | 0                 | 1 (9.1%)    | 0          |
| Hirsutism                       | 3 (16.7%)           | 0                 | 3 (27.3%)   | 0          |
| Gum hyperplasia                 | 3 (16.7%)           | 0                 | 2 (18.2%)   | 0          |
| Other*                          | 6 (33.3%)           | 0                 | 4 (36.4%)   | 4 (36.4%)  |

Results are reported as N (%)  

*Firth’s odds ratios with profile penalized likelihood confidence limits and p-values of tacrolimus vs. cyclosporine treatment groups are reported. Models are adjusted for differences in follow-up time.

*Other toxicities include hypertension (1), skin rash (1), transaminitis (2), nausea (1), tremors (1)
Our study is limited by its retrospective, uncontrolled design, small sample size, and different follow-up times for toxicity assessments. Further study with a prospective trial examining the use of tacrolimus with eltrombopag as first-line and later-line IST for aplastic anemia is warranted. However, in the absence of a prospective, randomized comparison, these data support the use of tacrolimus and eltrombopag as part of IST for AA.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Townsley DM et al (2017) “Eltrombopag added to standard immunosuppression for aplastic anemia,” (in eng), N Engl J Med 376(16):1540–1550. https://doi.org/10.1056/NEJMoA1613878

2. Scheinberg P, Nunez O, Weinstein B, Biancotto A, Wu CO, Young V, Hamilton BK, Kharlan-Dabaja MA, Marks DJ, Ringdén OTH, Socié G, Solh MM, Akpek G, Cairo MS, Chao NJ, Hayashi RJ, Nishihori T, Reshef R, Saad A, Shah T, Teshima T, Tallman MS, Wirk B, Spellman SR, Arora M, Martin PJ (2015) Tacrolimus versus cyclosporine after hematopoietic cell transplantation for acquired aplastic anemia. (in eng), Biol Blood Marrow Transplant 21(10):1776–1782. https://doi.org/10.1016/j.bbmt.2015.05.023

3. Boddu PC, Kadia TM (2017) “Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review,” (in eng), Expert Rev Hematol 10(5):433–448. https://doi.org/10.1080/17474086.2017.1313700

4. Bacigalupo A (2017) “How I treat acquired aplastic anemia,” (in eng), Blood 129(11):1428–1436. https://doi.org/10.1182/blood-2016-08-693481

5. Tisdale JF, Dunn DE, Maciejewski J (Jan 2000) Cyclophosphamide and other new agents for the treatment of severe aplastic anemia. (in eng), Semin Hematol 37(1):102–109

6. Muduma G, Saunders R, Odeyemi I, Pollock RF (2016) Systematic review and meta-analysis of tacrolimus versus cyclosporin as primary immunosuppression after liver transplant. (in eng), PLoS One 11(11):e0160421. https://doi.org/10.1371/journal.pone.0160421

7. Pennina L, Møller CH, Gustafsson F, Steinbrüchel DA, Glud C (Dec 2010) Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. (in eng), Eur J Clin Pharmacol 66(12):1177–1187. https://doi.org/10.1007/s00228-010-0902-6

8. Pennina L, Wettergren A, Chan AW, Steinbrüchel DA, Glud C (2012) Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients. (in eng), Cochrane Database Syst Rev (3):CD008852. https://doi.org/10.1002/14651858.CD008852.pub2

9. Pennina L, Penninga EI, Møller CH, Iversen M, Steinbrüchel DA, Glud C (2013) Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. (in eng), Cochrane Database Syst Rev (5):CD008817. https://doi.org/10.1002/14651858.CD008817.pub2

10. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC (2005) Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. (in eng), BMJ 331(7520):810. https://doi.org/10.1136/bmj.38569.471007.AE

11. Inamoto Y, Flowers MED, Wang T, Urbano-Ispizua A, Hemmer MT, Cutler CS, Couriel DR, Alousi AM, Antin JH, Gale RP, Gupta V, Hamilton BK, Kharlan-Dabaja MA, Marks DJ, Ringdén OTH, Socié G, Solh MM, Akpek G, Cairo MS, Chao NJ, Hayashi RJ, Nishihori T, Reshef R, Saad A, Shah T, Teshima T, Tallman MS, Wirk B, Spellman SR, Arora M, Martin PJ (2015) Tacrolimus versus cyclosporine after hematopoietic cell transplantation for acquired aplastic anemia. (in eng), Biol Blood Marrow Transplant 21(10):1776–1782. https://doi.org/10.1016/j.bbmt.2015.05.023

12. Wiederrrecht G, Lam E, Hung S, Martin M, Sigal N (Nov 1993) “The mechanism of action of FK-506 and cyclosporin A,” (in eng), Ann N Y Acad Sci 696:9–19

13. Mukherjee S, Mukherjee U (2009) “A comprehensive review of immunosuppression used for liver transplantation,” (in eng), J Transp Secur 2009:701464–701420. https://doi.org/10.1155/2009/701464

14. Alsultan A, Goldenberg NA, Kaiser N, Graham DK, Hays T (2009) Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children. (in eng), Pediatr Blood Cancer 52(5):626–630. https://doi.org/10.1002/pbc.21926

15. Macartney C, Freilich M, Odam I, Charpentier K, Dnor Y (2009) Complete response to tacrolimus in a child with severe aplastic anemia resistant to cyclosporin A. (in eng), Pediatr Blood Cancer 52(4):525–527. https://doi.org/10.1002/pbc.21751

16. Zhu X, Guan J, Xu J, Yin J, Zhao L, Zhang Y (2014) Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults. (in eng), Blood Cells Mol Dis 53(3):157–160. https://doi.org/10.1016/j.bcmd.2014.04.008

17. Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, Killick SB, Warren AJ, Foukani T, Aljurf M, al-Zahrani HA, Höchsmann B, Schafhausen P, Roth A, Frankze A, Brummendorf TH, Dafour C, Oneto R, Sedwick P, Barrois A, Kordasti S, Elebute MO, Mufti GJ, Socie G, European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party (2012) Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT severe aplastic anaemia working party. (in eng), Blood 119(23):5391–5396. https://doi.org/10.1182/blood-2012-04-07684

18. Shetty M, Narendra AM, Adiraju KP, Modugu NR (2016) Study of aplastic anaemia with cyclosporine in resource poor setting. (in eng), J Clin Diagn Res 10(6):OC15–OC18. https://doi.org/10.7860/JCDR/2016/16144.7952

19. Gluckman E et al (1992) Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. (in eng), Blood 79(10):2540–2546

20. Ilyas M, Colegio OR, Kaplan B, Sharma A (2017) Cutaneous toxicities from transplantation-related medications. (in eng), Am J Transplant 17(11):2782–2789. https://doi.org/10.1111/ajt.14337

21. Nankivell BJ, P Ng CH, O Connell PJ, Chapman JR (2016) Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. (in eng), Transplantation 100(8):1723–1731. https://doi.org/10.1097/TP.0000000000001243

22. Killcik SB, Bown N, Cavenagh J, Dokal I, Foukani T, Hill A, Hillmen P, Ireland R, Kulasekaraaraj A, Mufti G, Snowden JA,
Samarasinghe S, Wood A, Marsh JCW, the British Society for Standards in Haematology (2016) Guidelines for the diagnosis and management of adult aplastic anaemia. (in eng), Br J Haematol 172(2):187–207. https://doi.org/10.1111/bjh.13853

23. Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE (2012) Eltrombopag and improved hematopoiesis in refractory aplastic anemia. (in eng), N Engl J Med 367(1):11–19. https://doi.org/10.1056/NEJMoa1200931

24. Chiu V, Weitz IC, Hermel DJ (2017) Tacrolimus is effective immunosuppressive therapy in aplastic anemia. In: Blood : Journal of the American Society of Hematology, vol 130, ed.

25. Cheng H, Wang X, Zhou D, Cao J, Larochelle A, Xu KL (2019) Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia. (in eng), Ann Hematol 98(8):2009–2011. https://doi.org/10.1007/s00277-019-05658-2

26. Scheinberg P (2018) Activity of eltrombopag in severe aplastic anemia. (in eng), Hematology Am Soc Hematol Educ Program 2018(1):450–456. https://doi.org/10.1182/asheducation-2018.1.450

27. Maluf E, Hamerschlak N, Cavalcanti AB, Junior AA, Eluf-Neto J, Falcao RP, Lorand-Metze IG, Goldenberg D, Santana CL, de Oliveira Werneck Rodrigues D, Passos LNM, Rosenfeld LGM, Pitta M, Loggetto S, Feitosa Ribeiro AA, Velloso ED, Kondo AT, de Miranda Coelho EO, Pintao MCT, de Souza HM, Borbolla JR, Pasquini R (2009) Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case-control study. (in eng), Haematologica 94(9):1220–1226. https://doi.org/10.3324/haematol.2008.002642

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.